Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Other Non Operating Income (2019 - 2025)

Historic Other Non Operating Income for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $10.4 million.

  • Kymera Therapeutics' Other Non Operating Income rose 770.34% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.5 million, marking a year-over-year increase of 1369.54%. This contributed to the annual value of $38.0 million for FY2024, which is 10265.4% up from last year.
  • Latest data reveals that Kymera Therapeutics reported Other Non Operating Income of $10.4 million as of Q3 2025, which was up 770.34% from $8.1 million recorded in Q2 2025.
  • Kymera Therapeutics' Other Non Operating Income's 5-year high stood at $10.4 million during Q3 2025, with a 5-year trough of $98000.0 in Q2 2021.
  • For the 5-year period, Kymera Therapeutics' Other Non Operating Income averaged around $4.8 million, with its median value being $4.6 million (2023).
  • In the last 5 years, Kymera Therapeutics' Other Non Operating Income plummeted by 6618.91% in 2021 and then skyrocketed by 253724.14% in 2022.
  • Quarter analysis of 5 years shows Kymera Therapeutics' Other Non Operating Income stood at $145000.0 in 2021, then surged by 2537.24% to $3.8 million in 2022, then soared by 30.65% to $5.0 million in 2023, then surged by 101.4% to $10.1 million in 2024, then rose by 3.8% to $10.4 million in 2025.
  • Its Other Non Operating Income was $10.4 million in Q3 2025, compared to $8.1 million in Q2 2025 and $8.9 million in Q1 2025.